Literature DB >> 26870202

Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in a single patient: A case report.

Rongxing Zhou1, Minjia Zhang2, Nansheng Cheng1, Yong Zhou1.   

Abstract

Double primary hepatic cancer, consisting of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) located separately within a single liver simultaneously, is extremely rare. The present study reports a case of double hepatic nodules, in which HCC and ICC occurred simultaneously in the right hepatic lobe. The 47-year-old male patient, who was a carrier of hepatitis B virus, was admitted to our hospital for physical examination, which revealed two liver masses. The results of initial laboratory tests, including liver function tests, were within normal limits, with the exception of mildly elevated aspartate aminotransferase and alanine aminotransferase, and decreased albumin levels. α-fetoprotein was in the normal range, while carbohydrate antigen 19-9 was marginally elevated. Abdominal ultrasonography and enhanced computed tomography revealed two tumors located in segments (S) VI and VII of the liver, respectively, with malignant behavior. Examination of the two masses following resection of S VI and VII confirmed a diagnosis of combined HCC and ICC. After 8 months of follow-up, no signs of recurrence have been observed with chemical therapy.

Entities:  

Keywords:  diagnosis; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; mass; treatment

Year:  2015        PMID: 26870202      PMCID: PMC4727038          DOI: 10.3892/ol.2015.3896

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Combined liver cell and bile duct carcinoma.

Authors:  R A ALLEN; J R LISA
Journal:  Am J Pathol       Date:  1949-07       Impact factor: 4.307

3.  Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions.

Authors:  Marco Massani; Tommaso Stecca; Luca Fabris; Ezio Caratozzolo; Cesare Ruffolo; Alberto Furlanetto; Stuart Morton; Massimiliano Cadamuro; Mario Strazzabosco; Nicolò Bassi
Journal:  Oncol Rep       Date:  2013-06-26       Impact factor: 3.906

4.  Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.

Authors:  Z D Goodman; K G Ishak; J M Langloss; I A Sesterhenn; L Rabin
Journal:  Cancer       Date:  1985-01-01       Impact factor: 6.860

Review 5.  Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.

Authors:  Irinel Popescu; Traian Dumitrascu
Journal:  Langenbecks Arch Surg       Date:  2014-05-20       Impact factor: 3.445

6.  Intrahepatic cholangiocarcinoma arising in chronic advanced liver disease and the cholangiocarcinomatous component of hepatocellular cholangiocarcinoma share common phenotypes and cholangiocarcinogenesis.

Authors:  Jing Xu; Motoko Sasaki; Kenichi Harada; Yasunori Sato; Hiroko Ikeda; Ji-Hun Kim; Eunsil Yu; Yasuni Nakanuma
Journal:  Histopathology       Date:  2011-12       Impact factor: 5.087

Review 7.  Management of combined hepatocellular and cholangiocarcinoma.

Authors:  W T Kassahun; J Hauss
Journal:  Int J Clin Pract       Date:  2008-02-13       Impact factor: 2.503

8.  Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images.

Authors:  Yusuhn Kang; Jeong Min Lee; Seung Ho Kim; Joon Koo Han; Byung Ihn Choi
Journal:  Radiology       Date:  2012-07-12       Impact factor: 11.105

9.  Combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma: outcome after liver transplantation.

Authors:  Kishore Maganty; David Levi; Jang Moon; Pablo A Bejarano; Leopoldo Arosemena; Andreas Tzakis; Paul Martin
Journal:  Dig Dis Sci       Date:  2010-09-17       Impact factor: 3.487

10.  CEA monitoring in colorectal cancer is not a waste of time.

Authors:  David Mant; John Primrose
Journal:  BMJ       Date:  2014-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.